Advances in Therapy

, Volume 36, Issue 7, pp 1642–1656 | Cite as

Pharmacokinetic Drug Interactions Between Amlodipine, Valsartan, and Rosuvastatin in Healthy Volunteers

  • Sook Jin Seong
  • Boram Ohk
  • Woo Youl Kang
  • Mi-Ri Gwon
  • Bo Kyung Kim
  • Seungil Cho
  • Dong Heon Yang
  • Hae Won LeeEmail author
  • Young-Ran YoonEmail author
Original Research



Amlodipine, valsartan, and rosuvastatin are among the medications widely coadministered for the treatment of hyperlipidemia accompanied by hypertension. The aim of this study was to investigate the possible pharmacokinetic drug–drug interactions between amlodipine, valsartan, and rosuvastatin in healthy Korean male volunteers.


In this phase 1, open-label, multiple-dose, two-part, two-period, fixed-sequence study, the enrolled subjects were randomized into two parts (A and B). In part A (n = 32), each subject received one fixed-dose combination (FDC) tablet of amlodipine/valsartan 10 mg/160 mg alone for 10 consecutive days in period I, and the same FDC for 10 days with concomitant 7-day administration of 20 mg rosuvastatin in period II. In part B (n = 25), each subject received rosuvastatin alone for 7 days in period I, and the FDC for 10 days with concomitant 7-day administration of rosuvastatin in period II. In both parts, there was a 12-day washout between periods. Serial blood samples were collected for up to 72 h for amlodipine and rosuvastatin, and for up to 48 h for valsartan after the last dose of each period. The plasma concentrations of amlodipine, valsartan, and rosuvastatin were determined by using liquid chromatography–tandem mass spectrometry.


Fifty-seven subjects were enrolled; 30 and 25 subjects completed part A and part B, respectively. The geometric mean ratios and 90% confidence intervals for the maximum plasma concentration at steady state (Cmax,ss) and the area under the plasma concentration–time curve over the dosing interval at steady state (AUCτ,ss) were 0.9389 (0.9029–0.9763) and 0.9316 (0.8970–0.9675) for amlodipine, 0.7698 (0.6503–0.9114) and 0.7888 (0.6943–0.8962) for valsartan, and 0.9737 (0.8312–1.1407) and 0.9596 (0.8826–1.0433) for rosuvastatin, respectively. Of the 57 subjects enrolled in this study, 10 subjects experienced 13 adverse events (AEs); no severe or serious AEs were reported.


When amlodipine, valsartan, and rosuvastatin were coadministered to healthy volunteers, the pharmacokinetic exposure to valsartan was decreased, but no change in exposure to amlodipine and rosuvastatin occurred. All treatments were well tolerated.

Clinical Trial Registration CRIS KCT0001660.


KyungDong Pharmaceutical Corp. Ltd., Seoul, Republic of Korea.


Amlodipine Drug–drug interaction Rosuvastatin Valsartan 



The authors thank all participants of the study.


This study and article processing charges were sponsored by KyungDong Pharmaceutical Corp. Ltd., Seoul, Republic of Korea, and was supported by Grants from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI14C2750, HI15C0001), and the Industrial Core Technology Development Program (10051129, Development of the system for ADME assessment using radiolabeled compounds), funded by the Ministry of Trade, Industry & Energy (MOTIE, Korea). All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis.

Medical Writing and/or Editorial Assistance

Medical writing support was provided by Vikas Narang of Editage by Cactus Communications Inc. (Trevose, PA, USA), and was funded by KNUH CTC.


All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.


Sook Jin Seong, Boram Ohk, Woo Youl Kang, Mi-Ri Gwon, Bo Kyung Kim, Seungil Cho, Dong Heon Yang, Hae Won Lee, and Young-Ran Yoon have nothing to disclose.

Compliance with Ethics Guidelines

The study protocol was approved by the Institutional Review Board at Kyungpook National University Hospital (Daegu, Republic of Korea), and the study was performed in accordance with the ethical standards for studies in humans set out in the Declaration of Helsinki and its amendments, and the applicable guidelines for International Conference on Harmonization Good Clinical Practice, and local laws and regulations. Written informed consent was obtained from all individual subjects included in the study before their enrollment.

Data Availability

The data sets generated and/or analyzed during this study are not publicly available due to confidentiality of KyungDong Pharmaceutical Corp. Ltd., but are available from the corresponding author upon reasonable request.


  1. 1.
    National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–421.Google Scholar
  2. 2.
    Egan BM, Li J, Qanungo S, Wolfman TE. Blood pressure and cholesterol control in hypertensive hypercholestrolemic patients: national health and nutrition examination surveys 1988–2010. Circulation. 2013;128:29–41.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Kostis JB. The importance of managing hypertension and dyslipidemia to decrease cardiovascular disease. Cardiovasc Drugs Ther. 2007;21(4):297–309.CrossRefPubMedGoogle Scholar
  4. 4.
    Zhang PY. Review of new hypertension guidelines. Eur Rev Med Pharmacol Sci. 2015;19(2):312–5.PubMedGoogle Scholar
  5. 5.
    James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Rubio-Guerra AF, Castro-Serna D, Barrera CI, Ramos-Brizuela LM. Current concepts in combination therapy for the treatment of hypertension: combined calcium channel blockers and RAAS inhibitors. Integr Blood Press Control. 2009;2:55–62.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159–219.CrossRefPubMedGoogle Scholar
  8. 8.
    Canbakan B. Rational approaches to the treatment of hypertension: drug therapy-monotherapy, combination, or fixed-dose combination? Kidney Int Suppl (2011). 2013;3(4):349–51.CrossRefGoogle Scholar
  9. 9.
    Pfizer Pharmaceuticals Co. NOVASC drug label. Accessed 20 Aug 2018.
  10. 10.
    Abernethy DR. The pharmacokinetic profile of amlodipine. Am Heart J. 1989;118(5 Pt 2):1100–3.CrossRefPubMedGoogle Scholar
  11. 11.
    Meredity PA, Elliott HL. Clinical pharmacokinetics of amlodipine. Clin Pharmacokinet. 1992;22(1):22–31.CrossRefGoogle Scholar
  12. 12.
    Zhu Y, Wang F, Li Q, et al. Amlodipine metabolism in human liver microsomes and roles of CYP3A4/5 in the dihydropyridine dehydrogenation. Drug Metab Dispos. 2014;42(2):245–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Kim KA, Park PW, Park JY. Effect of ABCB1 (MDR 1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects. Br J Clin Pharmacol. 2007;63(1):53–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Zuo XC, Zhang WL, Yuan H, et al. ABCB1 polymorphism and gender affect the pharmacokinetics of amlodipine in Chinese patients with essential hypertension: a population analysis. Drug Metab Pharmacokinet. 2014;29(4):305–11.CrossRefPubMedGoogle Scholar
  15. 15.
    Takara K, Matsubara M, Yamamoto K, et al. Differential effects of calcium antagonists on ABCG2/BCRP-mediated drug resistance and transport in SN-38-resistant HeLa cells. Mol Med Rep. 2012;5(3):603–9.PubMedGoogle Scholar
  16. 16.
    Novartis Pharmaceuticals Co. Diovan drug label. pdf. Accessed 22 Aug 2018.
  17. 17.
    Zaid AN, Natur S, Qaddomi A, et al. Formulation and bioequivalence of two valsartan/amlodipine immediate release tablets after a single oral administration. Pak J Pharm Sci. 2014;27(4):755–62.PubMedGoogle Scholar
  18. 18.
    Hanna I, Alexander N, Crouthamel MH, et al. Transport properties of valsartan, sacubitril and its active metabolite (LBQ657) as determinants of disposition. Xenobiotica. 2018;48(3):300–13.CrossRefPubMedGoogle Scholar
  19. 19.
    Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1—executive summary. J Clin Lipidol. 2014;8(5):473–88.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92(2):152–60.CrossRefPubMedGoogle Scholar
  21. 21.
    Crestor (rosuvastatin calcium) tablets [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2013. Accessed 24 Aug 2018.
  22. 22.
    Martin PD, Warwick MJ, Dane AL, et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther. 2003;25(11):2822–35.CrossRefPubMedGoogle Scholar
  23. 23.
    Crouse JR 3rd. An evaluation of rosuvastatin: pharmacokinetics, clinical efficacy and tolerability. Expert Opin Drug Metab Toxicol. 2008;4(3):287–304.CrossRefPubMedGoogle Scholar
  24. 24.
    Son J, Guk J, Kim Y, et al. Pharmacokinetic interaction between rosuvastatin, telmisartan, and amlodipine in healthy male Korean subjects: a randomized, open-label, muptiple-dose, 2-period crossover study. Clin Ther. 2016;38(8):1845–57.CrossRefPubMedGoogle Scholar
  25. 25.
    Jung JA, Noh YH, Jin S, et al. Pharmacokinetic interaction between pitavastatin and valsartan: a randomized, open-labeled crossover study in healthy male Korean volunteers. Clin Ther. 2012;34(4):958–65.CrossRefPubMedGoogle Scholar
  26. 26.
    DeGorter MK, Urquhart BL, Gradhand U, Tirona RG, Kim RB. Disposition of atorvastatin, rosuvastatin, and simvastatin in Oatp1b2–/– mice and intraindividual variability in human subjects. J Clin Pharmacol. 2012;52(11):1689–97.CrossRefPubMedGoogle Scholar
  27. 27.
    Ngo L, Cho HY, Lee YB. Effects of hydrochlorthazide and amlodipine on single oral dose pharmacokinetics of valsartan in healthy Korean subjects: population model-based approach. Eur J Pharm Sci. 2018;118:154–64.CrossRefPubMedGoogle Scholar
  28. 28.
    Jung JA, Lee SY, Kim JR, et al. A pharmacokinetic and pharmacodynamics drug interaction between rosuvastatin and valsartan in healthy subjects. Drug Des Dev Ther. 2015;9:745–52.CrossRefGoogle Scholar
  29. 29.
    Birmingham BK, Bujac SR, Elsby R, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States. Eur J Clin Pharmacol. 2015;71:329–40.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Healthcare Ltd., part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Molecular Medicine, School of MedicineKyungpook National UniversityDaeguRepublic of Korea
  2. 2.Department of Clinical PharmacologyKyungpook National University HospitalDaeguRepublic of Korea
  3. 3.Division of Cardiology, Department of Internal MedicineKyungpook National University HospitalDaeguRepublic of Korea

Personalised recommendations